Varian Medical Systems (VAR) Getting Somewhat Favorable Press Coverage, Report Finds
News coverage about Varian Medical Systems (NYSE:VAR) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Varian Medical Systems earned a news impact score of 0.21 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.0274662017254 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Varian Announces Penn Medicine Treats World’s First Patient on Halcyon System (finance.yahoo.com)
- Form 4/A VARIAN MEDICAL SYSTEMS For: Sep 12 Filed by: KENNEDY KOLLEEN T (streetinsider.com)
- Varian Medical : Ranks First in Overall Manufacturer, System, and Service Performance in 2017 Survey of Radiation Oncology Professionals (4-traders.com)
- Varian Ranks First in Overall Manufacturer, System, and Service Performance in 2017 Survey of Radiation Oncology Professionals (finance.yahoo.com)
- Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5 (zacks.com)
Varian Medical Systems (VAR) opened at 105.19 on Friday. The company has a market cap of $9.66 billion, a price-to-earnings ratio of 34.62 and a beta of 0.58. The company has a 50-day moving average of $102.10 and a 200-day moving average of $97.84. Varian Medical Systems has a one year low of $75.20 and a one year high of $107.87.
Varian Medical Systems (NYSE:VAR) last issued its earnings results on Wednesday, July 26th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.09. The business had revenue of $662.40 million during the quarter, compared to analyst estimates of $663.86 million. Varian Medical Systems had a return on equity of 24.70% and a net margin of 9.50%. Varian Medical Systems’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 earnings per share. Equities research analysts expect that Varian Medical Systems will post $3.93 EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on VAR shares. BidaskClub downgraded shares of Varian Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 29th. Royal Bank Of Canada restated a “hold” rating and issued a $100.00 price target on shares of Varian Medical Systems in a research note on Friday, September 1st. BTIG Research downgraded shares of Varian Medical Systems from a “buy” rating to a “neutral” rating in a research note on Thursday, September 7th. They noted that the move was a valuation call. Robert W. Baird restated a “hold” rating and issued a $99.00 price target on shares of Varian Medical Systems in a research note on Monday, August 28th. Finally, Zacks Investment Research upgraded shares of Varian Medical Systems from a “hold” rating to a “buy” rating and set a $117.00 price target on the stock in a research note on Tuesday, June 27th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company. Varian Medical Systems presently has an average rating of “Hold” and a consensus price target of $97.39.
ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/24/varian-medical-systems-var-getting-somewhat-favorable-press-coverage-report-finds.html.
In other Varian Medical Systems news, SVP John W. Kuo sold 863 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $104.48, for a total value of $90,166.24. Following the completion of the sale, the senior vice president now owns 28,224 shares of the company’s stock, valued at $2,948,843.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dow R. Wilson sold 15,060 shares of the company’s stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $103.37, for a total value of $1,556,752.20. Following the completion of the sale, the insider now directly owns 81,836 shares of the company’s stock, valued at approximately $8,459,387.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,787 shares of company stock valued at $5,600,457. 0.91% of the stock is owned by insiders.
Varian Medical Systems Company Profile
Varian Medical Systems, Inc is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy.
Receive News & Ratings for Varian Medical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.